I agree.I think once their combos start to take off with news,so will the stock.They can still be bought out by JNJ
or anybody else willing to pay the right price
In that deal, J&J acquired the rights to Achillion's HCV franchise, including ACH-3422, a drug that Achillion was hoping to use alongside ACH-3102 instead of Sovaldi in future trials.
Because J&J already has a strong HCV research program that includes the prior-generation therapy Incivek, the more recently-approved Olysio, as well as assets acquired when it bought Alios last year, all of which can be combined with Achillion's pipeline, investors may not want to count Achillion out just yet.
If J&J can craft a shorter-duration, next-generation HCV drug, Achillion could receive up to $1.1 billion in milestones and mid-teens to low-20s royalties on eventual sales. Because J&J also took a $225 million equity stake in Achillion at a price of $12.25 per share, Achillion's current $8.69 price and $1.02 billion market cap could ultimately be too low.
They are raking in billions with growth all over and soon to be all over the planet
So be prepared to print 91..But realistically.Fcaebook PRINTS MONEY!!
I saw that and thought the same..BUT.If it docent close and runs higher..Thats a sign of real strength ..Maybe 91.50 92..then it will try to take out 100.00
Most people can't wrap their head around it..The next Apple nd or Google..120. near term..
I laugh at theses people